en · de · es · fr · pt
aod-9604-notes.peptides9000.com › Info › Regulatory And Analytical Context — 2026 Update

Regulatory And Analytical Context — 2026 Update

By Editorial Desk · published 2026-05-23 · last reviewed 2026-06-26 · Info

If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-06-26. Numbers and descriptions here follow the published literature rather than marketing material.

Regulatory and Analytical Context

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Handling, Analysis, and Quality Control

AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.

Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.

Aod-9604 at a glance

PropertyValueNotes
Regulatory statusNot approved as a medicineStatus varies by country; prohibited in sport.
Common storage temperature2–8 °C for lyophilized powderProtect from light and moisture; follow supplier instructions.
Typical analytical methodLC-MS/MSUsed for identification and quantification in biological samples.
Purity assessmentHPLC and mass spectrometryReverse-phase HPLC is common for peptide purity.
Common synonymsAOD9604; hGH 176-191 fragmentNaming conventions differ across studies.

Background And Research Context

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

Related pages on this site

Handling And Analytical Properties

AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.

Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.

Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.

Identity and Research Context

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Reference notes

=== Exhibits === The museum debuted a new exhibit on November 22, 2013. It consists of the engine of the Missouri Packet, the first steamboat to sink in the Missouri River in 1820. The Hawleys excavated its engine in 1987, just outside the small town of Arrow Rock, Missouri. It did not yield many other artifacts, yet still inspired the Hawleys to continue their quest for sunken steamboats. David Hawley told The Kansas City Star, "An engine like this has never been on display." He believes it to be the oldest extant maritime steam engine in the United States. In January 2013, the museum was closed for the first time in its 20-year history, to repair the ceiling and have the displays cleaned, reorganized, and expanded.

In 2025, DFI Retail Group sold the Singaporean food retailing business (including Cold Storage brand) to Macrovalue Pte Ltd. In August 2026, Cold Storage launched Cold Storage On The Go, a convenience store format, at an Esso station on East Coast Road. The company planned to introduce the format at all 58 Esso stations in Singapore during 2026, replacing FairPrice Group's convenience stores.

== Use as a biochemical marker for bone formation == As osteoblasts produce osteocalcin, it is often used as a marker for the bone formation process. Higher serum osteocalcin levels have been observed to correlate relatively well with increases in bone mineral density during treatment with anabolic bone formation drugs for osteoporosis, such as teriparatide. In many studies, osteocalcin is used as a preliminary biomarker for the effectiveness of a given drug on bone formation. For instance, one study that aimed to study the efficacy of a glycoprotein called lactoferrin on bone formation used osteocalcin to measure osteoblast activity.

Sources: en.wikipedia.org

Reference notes

Severe sexual dysfunction, including loss of libido, anorgasmia, lack of vaginal lubrication, and erectile dysfunction, is one of the most commonly encountered adverse effects of treatment with paroxetine and other SSRIs. While early clinical trials suggested a relatively low rate of sexual dysfunction, more recent studies in which the investigator actively inquires about sexual problems suggest that the incidence is higher than 70%. Paroxetine has consistently been found to have the highest rate of sexual side effects among the SSRIs. In some patients, these effects persist after discontinuation of the drug, a condition known as post-SSRI sexual dysfunction (PSSD). Characteristic symptoms include genital numbness, pleasureless or weak orgasm, loss of libido, and erectile dysfunction; non-sexual symptoms such as emotional blunting and cognitive impairment may also occur. The condition can arise after even brief exposure to a serotonin reuptake inhibitor and may persist indefinitely; there is currently no established treatment. The DSM-5 noted in 2013 that serotonin reuptake inhibitor-induced sexual dysfunction may persist after the agent is discontinued. Paroxetine was among the earliest SSRIs to be associated with persistent sexual dysfunction in the peer-reviewed literature. A 2023 retrospective cohort study of over 12,000 males estimated the risk of irreversible sexual dysfunction at approximately 0.46% of patients treated with serotonergic antidepressants, including SSRIs, though the actual prevalence remains uncertain and the condition is likely underreported.

==== Canada ==== As of 11 April 2020, access in Canada was available only through clinical trials. Health Canada approved requests to treat twelve people with remdesivir under the department's special-access program (SAP). Additional doses of remdesivir are not available through the SAP except for pregnant women or children with confirmed COVID‑19 and severe illness. In June 2020, Health Canada received an application from Gilead for the use of remdesivir for treating COVID‑19. On 27 July 2020, Health Canada conditionally approved the application. In September 2020, Minister of Public Services and Procurement Anita Anand announced that Canada had entered into a deal to obtain up to 150,000 vials of remdesivir from Gilead starting in October. As of 8 October, remdesivir was still not widely available in Alberta, because Alberta Health Services was undertaking a "formulary review" to be completed by mid-November.

== Odd-chain fatty acids == Odd-chain fatty acids (OCFAs) are those fatty acids that contain an odd number of carbon atoms. The most common OCFAs are the saturated C15 and C17 derivatives, respectively pentadecanoic acid and heptadecanoic acid. The synthesis of even-chained fatty acid synthesis is done by assembling acetyl-CoA precursors, however, propionyl-CoA instead of acetyl-CoA is used as the primer for the biosynthesis of long-chain fatty acids with an odd number of carbon atoms.

ISO 2171: Cereals, pulses and by-products — Determination of ash yield by incineration; ISO 3593: Starch — Determination of ash; ISO 928: Spices and condiments - Determination of total ash; and ISO 936: Meat and meat products - Determination of total ash. Examples of ash content methods for the determination of ash in other solids include

Sources: en.wikipedia.org

Reference notes

There is a consensus among the world's major medical organizations and in the academic literature that circumcision is an efficacious intervention for HIV prevention in high-risk populations if carried out by medical professionals under safe conditions. In 2007, the WHO and the Joint United Nations Programme on HIV/AIDS (UNAIDS) recommended adolescent and adult circumcision as part of a comprehensive program for prevention of HIV transmission in areas with high endemic rates of HIV, as long as the program includes "informed consent, confidentiality, and absence of coercion"—known as voluntary medical male circumcision, or VMMC. In 2010, this expanded to routine neonatal circumcision, as long as the infant's parents consented. In 2020, the WHO again concluded that male circumcision is an efficacious intervention for HIV prevention and that male circumcision is an essential strategy, in addition to other measures, to prevent heterosexually acquired HIV infection in men. Eastern and southern Africa had a particularly low prevalence of circumcised males. This region has a disproportionately high HIV infection rate, with a significant number of infections stemming from heterosexual transmission. As a result, the promotion of prophylactic circumcision has been a priority intervention in that region since the WHO's 2007 recommendations. The International Antiviral Society–USA also suggests circumcision be discussed with men who have insertive anal sex with men, especially in regions where HIV is common.

One specialized form of fresh-produce train that existed in the UK was the milk train, which, using specialized chilled, glass-lined wagons, remained in service until 1981. Like many railways around the world, modern UK railways do ship specialized refrigerated containers on intermodal trains, with such trains now taking over the role again from long-distance trucking on hub-to-hub routes to reduce carbon footprint. DB Cargo UK runs Europe's longest-distance single-operator handled train from Valencia, Spain to Barking in East London twice weekly, in partnership with Eddie Stobart Logistics and retailer Tesco's, shipping fresh fruit and produce 1,800 km (1,118 mi) in refrigerated ISO containers.

==== Exfoliation with supercritical carbon dioxide ==== Liquid-phase exfoliation can also be done by a less-known process of intercalating supercritical carbon dioxide (scCO2) into the interstitial spaces in the graphite lattice, followed by rapid depressurization. The scCO2 intercalates easily inside the graphite lattice at a pressure of roughly 100 atm. Carbon dioxide turns gaseous as soon as the vessel is depressurized and makes the graphite explode into few-layered graphene. This method may have multiple advantages: being non-toxic, the graphite does not have to be chemically treated in any way before the process, and the whole process can be completed in a single step as opposed to other exfoliation methods.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 approved for medical use?

No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.

Why is it banned in sports?

The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.

How is AOD-9604 detected?

Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.

How is AOD9604 typically stored?

Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.

Network